A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
ABSTRACTCombinatorial strategies, such as targeting different immune checkpoint receptors, hold promise to increase the breadth and duration of the response to cancer therapy. Here we describe the preclinical evaluation of CTX-8371, a protein construct which combines PD-1 and PD-L1 targeting in one...
Main Authors: | Diana I. Albu, Benjamin J. Wolf, Yan Qin, Xianzhe Wang, Amy Daniel Ulumben, Mei Su, Vivian Li, Eirene Ding, Jose Angel Gonzalo, Jason Kong, Ruturaj Jadhav, Nelly Kuklin, Alberto Visintin, Bing Gong, Thomas J. Schuetz |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2024.2316945 |
Similar Items
-
A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer
by: Ander Puyalto, et al.
Published: (2023-09-01) -
Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1
by: Joseph Mabbitt, et al.
Published: (2023-08-01) -
Immuno-PET Imaging of Tumour PD-L1 Expression in Glioblastoma
by: Gitanjali Sharma, et al.
Published: (2023-06-01) -
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
by: Tianye Li, et al.
Published: (2024-03-01) -
نقش PD-1/ PD-L1 و Anti-PD-1/ PD-L1 در پیشرفت و سرکوب سرطان
by: نرگس عبدالهی, et al.
Published: (2023-11-01)